Recombinant Human Erythropoietin Injection can promote the transformation of immature erythrocytes in bone marrow to mature erythrocytes faster, and is commonly used clinically for the treatment of anemia caused by various renal diseases, also known as renal anemia. It is also applied to anemia caused by chemotherapy of various malignant tumors, such as anemia caused by chemotherapy of leukemia, which can be improved by recombinant human erythropoietin injection in addition to red blood cell infusion. However, some people may experience some adverse reactions when applying recombinant human erythropoietin injection, which often manifest as low fever, headache and weakness, but the condition is usually mild and does not require special treatment. In addition, some people may experience allergy when applying recombinant human erythropoietin injection, which may manifest as rash, urticaria, or anaphylactic shock in severe cases. Therefore, it is best to apply it in a hospital for the first time and under the guidance of a physician with clinical experience.